Opinions expressed by Entrepreneur contributors are their own. When he was 15 years old, Max Clarke would wake up to find blood pouring from his nose. The nosebleeds were relentless, sometimes happening multiple times a week. Doctors couldn't diagnose it. By the time Clarke got to university, he was exhausted and still without answers. So
Stablecoin companies operating in Hong Kong posted double-digit losses on Friday amid local regulatory shifts and a broader market correction. Bright Smart Securities & Commodities Group fell nearly 20% on Friday, according to Google Finance data. Yunfeng Financial Group dropped more than 16% during the trading session, while Guotai Junan International Holdings slid 11% and
Sun Pharmaceutical Industries Ltd's revenue from operations for the April-June period beat Street expectations to rise 9.4% year-on-year to ₹13,851 crore. However, the drugmaker's net profit fell on exceptional items including settlement costs in a pricing antitrust litigation in the US and discontinuing clinical studies on one of its drugs. The company posted a net
Opinions expressed by Entrepreneur contributors are their own. When he was 15 years old, Max Clarke would wake up to find blood pouring from his nose. The nosebleeds were relentless, sometimes happening multiple times a week. Doctors couldn't diagnose it. By the time Clarke got to university, he was exhausted and still without answers. So
Stablecoin companies operating in Hong Kong posted double-digit losses on Friday amid local regulatory shifts and a broader market correction. Bright Smart Securities & Commodities Group fell nearly 20% on Friday, according to Google Finance data. Yunfeng Financial Group dropped more than 16% during the trading session, while Guotai Junan International Holdings slid 11% and
Sun Pharmaceutical Industries Ltd's revenue from operations for the April-June period beat Street expectations to rise 9.4% year-on-year to ₹13,851 crore. However, the drugmaker's net profit fell on exceptional items including settlement costs in a pricing antitrust litigation in the US and discontinuing clinical studies on one of its drugs. The company posted a net
Texas Democrats Leave State to Stop Republicans’ Redistricting Plan
FeaturedNew YorkTexas Democrats Leave State to Stop Republicans’ Redistricting Plan